Markets
Nike stock moves

Nike’s stock fell 20% on Friday

There isn’t just one issue bothering Nike investors

On Friday, shares in Nike dropped some 20%. That’s the worst day in Nike’s 4+ decades as a public company — a period that’s seen the athletic brand survive recessions, pandemics, supply chain issues, and scandals. The sharp fall came after the world’s most valuable provider of shoes and stuff-to-sweat-in forecast that sales are expected to drop about 10% in its current quarter.

As Nate Becker astutely observes, that is unusual for Nike not just because the company almost always grows its sales — which topped $51 billion last year — but because this quarter is an Olympic quarter. That means hundreds of Swoosh-adorned athletes will be trying to run, jump, climb, kayak, and pole-vault their way into the history books, to mention but a few of the 329 events that will feature in the upcoming Paris games. Per Becker:

An analysis of financial data going back to the 2000 summer games in Sydney shows that Nike’s sales during Olympic quarters have risen an average of 9.9%, slightly higher than an average of 7.9% during non-Olympic quarters. So a drop of 10% is especially abnormal.

So, why is Nike struggling so much?

The bad news for the company is that there isn’t just one factor being cited. Its classic footwear lines are struggling, demand in China is soft, sales and traffic to its digital properties are down, and the company is expecting to sell less to wholesalers. One factor, at least in its athletic shoe division, is the rise of competitors like On Running and Hoka — two brands that are at the forefront of the boom in “running culture”, as a growing number of communities come together across America, and indeed the world, to embrace the simplest of athletic endeavors.

More Markets

See all Markets
markets

IREN drops on convertible debt offering

Shares of crypto miner and AI compute provider IREN dropped after the Australia-based, US-listed company said late Tuesday that it would sell $875 million in convertible senior debt.

The announcement came late in the trading day and caused a sell-off in the aftermarket session that continued into Wednesday trading.

The offering makes sense; the company can probably get some fairly cheap capital after its shares doubled over the last month.

But it exposes shareholders to some dilution risk if buyers of the hybrid securities do convert them into equity, which explains the market reaction.

The offering makes sense; the company can probably get some fairly cheap capital after its shares doubled over the last month.

But it exposes shareholders to some dilution risk if buyers of the hybrid securities do convert them into equity, which explains the market reaction.

markets

Tempus AI shares surge to all-time high

Shares of Tempus AI jumped over 7% Wednesday to reach an all-time high of $99.90. Shares of the AI medical diagnostics company are up over 191% for the year so far.

The company has recently announced a flurry of FDA clearances for its technologies. Most recently, on September 22, Tempus AI was granted FDA clearance for its Tempus xR IVD device, which is used to tailor cancer therapies.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.